Eli Lilly and Co

Most Recent

  • Is Eli Lilly or LLY Stock a Buy or Sell?
    Healthcare

    Eli Lilly Stock Looks Like a Buy on Dips Amid Strong Growth Outlook

    By Ambrish Shah
  • Eli Lilly's Antibody Therapy is Promising, Lilly to Buy Prevail Therapeutics
    Healthcare

    Eli Lilly Will Buy Prevail Therapeutics, COVID-19 Antibody Therapy Is Promising

    By Ambrish Shah
  • eli lilly stock down earnings
    Financials

    Should You Buy Eli Lilly Stock After Its Q3 Earnings?

    By Ruchi Gupta
  • eli lilly covid  treatments
    Healthcare

    Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up

    By Ambrish Shah
  • uploads///stock picture HJHQsQohM
    Consumer

    Wellington Management: Analyzing Its Top Holdings

    Wellington Management filed its 13F on Wednesday. Based on the filing, the market value of total publicly traded securities was around $443.45 billion.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Consumer

    How Are Citadel Advisors Hedging their Portfolio?

    Kenneth Cordele Griffin is the CEO of investment management firm Citadel Advisors LLC. He is the hedge fund manager and he founded Citadel in 1990. 

    By Rabindra Samanta
  • uploads///AdobeStock_
    Consumer

    Tech Movers: Fitbit, Roku, and Datadog Lead Gains

    The broader markets were subdued today. However, tech stocks Datadog (DDOG), Roku (ROKU) and Fitbit (FIT) gained significantly. Here’s why.

    By Adam Rogers
  • uploads///Apple Watch
    Company & Industry Overviews

    New Apple Watch Features to Focus on Digital Health

    Apple (AAPL) has partnered with Eli Lily (LLY) to research whether the iPhone and Apple Watch can identify Alzheimer’s and dementia among users.

    By Adam Rogers
  • uploads///biochemistry biology blue
    Company & Industry Overviews

    Pain and Immunology: Eli Lilly’s Key Growth Areas

    In the first quarter, Emgality, Eli Lilly and Company’s (LLY) migraine prophylaxis drug, reported revenue of $14 million, of which $12.0 million came from the US market.

    By Margaret Patrick
  • uploads///scientist _
    Company & Industry Overviews

    How Is Eli Lilly’s Revenue Trending in 2019?

    During its first-quarter earnings investor presentation, Eli Lilly and Company (LLY) guided for revenue of $22.0 billion–$22.5 billion in 2019.

    By Margaret Patrick
  • uploads///analysis background bacteria
    Company & Industry Overviews

    What Analysts Recommend for LLY and AMGN

    Eli Lilly and Company (LLY) is down 0.20%, and Amgen (AMGN) is down 3.88% in 2019 on a year-to-date basis. Investors seem disappointed with the first-quarter results of both companies.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug

    In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Analysts Still Favor Eli Lilly and Company Stock

    Wall Street analysts have set Eli Lilly’s 12-month consensus target price at $122, 2.59% lower than the company’s closing price on March 18.

    By Margaret Patrick
  • uploads///business _
    Company & Industry Overviews

    Why Eli Lilly Stock Fell Yesterday

    Eli Lilly stock has been highly volatile since March 4.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What are AstraZeneca’s Key Growth Drivers?

    In fiscal 2018, AstraZeneca’s (AZN) revenue fell 2% YoY (year-over-year) to $22.09 billion on a CER (constant-exchange-rate) and reported basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt

    In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported effective tax rates of 3% and $15.98%, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing AstraZeneca’s and Eli Lilly’s Dividends

    In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported dividends per share of $1.40 and $2.25, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?

    In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth

    In its fourth-quarter earnings investor presentation, AstraZeneca (AZN) guided for core EPS of $3.50–$3.70 in fiscal 2019, expecting robust YoY (year-over-year) product sales growth and productivity improvements.

    By Margaret Patrick
  • uploads///anatomical _
    Company & Industry Overviews

    Analysts’ Recommendations for AstraZeneca and Eli Lilly

    Most analysts recommend “buy” for AstraZeneca and Eli Lilly.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ELAN or ZTS: Who Is Expected to Report Faster EPS Growth?

    In its fourth-quarter earnings investor presentation, Elanco Animal Health (ELAN) reiterated its fiscal 2019 GAAP and non-GAAP EPS guidance of $0.36–$0.48 and $1.02–$1.12, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?

    On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.

    By Margaret Patrick
  • uploads///Part
    Healthcare

    Moat Index: Dramatic Sector Allocation Shift in 2018

    The healthcare sector dominated the sector weighting for the Morningstar Wide Moat Index in 2018. The sector returned ~5% in 2018.

    By VanEck
  • uploads///Graph
    Company & Industry Overviews

    What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?

    In its fourth-quarter earnings investor presentation, Eli Lilly (LLY) highlighted its newer products such as Emgality, Verzenio, Olumiant, Lartruvo, Taltz, Basaglar, Jardiance, Trulicity, and Cyramza as its key drivers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer and Eli Lilly: How Dividends and Tax Rates Stack Up

    Pfizer (PFE) and Eli Lilly (LLY) reported dividends per share of $1.36 and $2.25 in fiscal 2018, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Who Is Controlling Expenses Better?

    In its fourth-quarter earnings investor presentation, Pfizer (PFE) guided for adjusted cost of sales as a percentage of revenues of 20.8% to 21.8% for fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Who Is Expected to Report Higher EPS Growth?

    In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for non-GAAP diluted EPS of $2.82–$2.92 for fiscal 2019 excluding the impact of profits and losses associated with equity investments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?

    In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019.

    By Margaret Patrick
  • uploads///medical _
    Company & Industry Overviews

    What Analysts Recommend for Pfizer and Eli Lilly in February

    Since its fourth-quarter earnings release, Pfizer stock has risen 4.48%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Eli Lilly and Loxo: A Robust Oncology Pipeline for Future Years

    Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Loxo Oncology Is Expected to Boost Eli Lilly’s Revenue in 2019

    Eli Lilly and Company (LLY) expects its Loxo Oncology (LOXO) acquisition to become revenue accretive starting in 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts Recommending for Eli Lilly and Loxo Oncology?

    Eli Lilly and Company (LLY) has entered into an agreement to acquire Loxo Oncology (LOXO) for a net consideration of $7.2 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Which Company Has the Better Dividend Policy?

    On its third-quarter earnings conference call, Pfizer (PFE) reported the return of $15.0 billion in dividends by way of share repurchases as of the end of October 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Which Company Is More Cost Efficient?

    On its third-quarter earnings conference call, Pfizer (PFE) said it expected its cost of sales as a percentage of its revenue to fall in the range of 20.8%–21.3%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Which Company Has Better Margins?

    In November 2018, Pfizer announced a hike in the list prices of 10% (or 41) of the medicines in its drug portfolio starting on January 15, 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Whose Earnings Are Seeing Better Growth?

    On its third-quarter earnings conference call, Pfizer (PFE) said that it expected its 2018 adjusted EPS to be in the range of $2.98–$3.02.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Whose Revenue Is Growing More Quickly?

    On its third-quarter earnings conference call, Pfizer (PFE) narrowed its 2018 revenue guidance range to $53.0 billion–$53.7 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Eli Lilly in January

    Eli Lilly and Company (LLY) is a leading large pharmaceutical company with a total market cap of $117.91 billion.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    Why Loxo Oncology Has Surged More than 65% Today

    Earlier today, American pharmaceutical giant Eli Lilly and Company (LLY) announced its acquisition of Loxo Oncology (LOXO).

    By Jitendra Parashar
  • uploads///Ibrance
    Company & Industry Overviews

    This Drug Is Expected to Be a Significant Driver for Pfizer

    In the first nine months of this year, Pfizer’s (PFE) Ibrance revenue grew 24% YoY (year-over-year) to $3.0 billion from $2.4 billion.

    By Daniel Collins
  • uploads///IONS
    Company & Industry Overviews

    Do Analysts See Any Upside for Ionis Stock?

    Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds.”

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Ionis’s Performance

    Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.

    By Kenneth Smith
  • uploads///BIIB
    Company & Industry Overviews

    Do Analysts See Any Upside for Biogen Stock?

    Of the 29 analysts covering Biogen (BIIB), 20 have given it “buy” or higher ratings, and nine have given it “hold” ratings.

    By Kenneth Smith
  • uploads///SGEN
    Company & Industry Overviews

    What Seattle Genetics’ Bottom-Line Trend Indicates

    In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How’s Seattle Genetics Positioned?

    Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Ajovy Is a New Growth Driver for Teva Pharmaceutical

    On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy.

    By Margaret Patrick
  • uploads///Eli Lilly
    Company & Industry Overviews

    Analyzing Eli Lilly’s Stock Price and Financial Performance

    On November 16, Eli Lilly’s (LLY) stock price closed at $113.83, which represents ~1.45% growth from its close of $112.20 on November 15.

    By Daniel Collins
  • uploads///CLVS
    Company & Industry Overviews

    Gauging Analysts’ Views on Clovis Stock

    In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///Januvia
    Company & Industry Overviews

    A Look at Merck’s Diabetes and Women’s Health Business

    Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.

    By Daniel Collins
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi: Analysts’ Recommendations on October 30

    As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”

    By Mike Benson
  • uploads///BMY
    Company & Industry Overviews

    A Look at the Performances of BMY’s Established Brands

    The sales of Bristol-Myers Squibb’s Baraclude fell from $264.0 million in the third quarter of 2017 to $175.0 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///Invega
    Company & Industry Overviews

    How JNJ’s Invega Sustenna and Risperdal Consta Performed

    Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Pfizer: Analysts Expect Revenue Growth in Q3

    Analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to the third quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Pfizer’s Current Valuation?

    Pfizer is trading at a forward PE ratio of ~14.5x on October 18—compared to the industry average of ~15.7x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Dividends and Earnings Quality

    Pfizer’s dividend yield is 3.15%. The company’s historical dividend yield was 3.53% in 2017, while the five-year average yield is 3.44%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Market Cap and Shareholding Pattern

    Pfizer’s total shares outstanding are ~5.862 billion. There are ~5.859 billion free-floating shares—nearly 99.95% of the total outstanding shares.

    By Mike Benson
  • uploads///headache _
    Company & Industry Overviews

    Analyzing Pfizer’s Stock Performance in October

    Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17.

    By Mike Benson
  • uploads///Merck earnings
    Earnings Report

    What’s Expected for Merck’s Q3 2018 Earnings

    Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018.

    By Daniel Collins
  • uploads///Bausch
    Company & Industry Overviews

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

    By Daniel Collins
  • uploads///valuation
    Company & Industry Overviews

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Novartis’s Valuation on October 9

    Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Assessing Novartis’s Performance in October So Far

    Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Amgen’s Stock Performance and Estimates after Q3 2018

    Analysts expect Amgen’s (AMGN) stock price to fall ~1.4% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Pfizer Stock Fare in Q3 2018?

    Nineteen analysts currently track Pfizer stock. The consensus rating for Pfizer stands at 2.63, which represents a “hold.”

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Eli Lilly’s Stock Performance and Estimates for Q3 2018

    Sixteen analysts currently track Eli Lilly (LLY) stock. Two analysts recommend a “strong buy,” six analysts recommend a “buy,” and eight analysts recommend a “hold.”

    By Mike Benson
  • uploads///Part
    Company & Industry Overviews

    Mylan Launches Its Generic Brevibloc Injection

    Mylan announced the launch of its generic Brevibloc injection in single-dose bags on September 13.

    By Sarah Collins
  • uploads///valuation multiples
    Company & Industry Overviews

    Does Mylan’s Low Valuation Provide a ‘Buy’ Opportunity?

    On September 26, Mylan had a 12-month forward PEG ratio of ~0.94x.

    By Sarah Collins
  • uploads///pills _
    Company & Industry Overviews

    Teva Announces First-to-File Launch of Generic Cialis

    Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    How GlaxoSmithKline’s Pharmaceutical Business Performed

    GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.

    By Mike Benson
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Sanofi Stock Up 2.8% in September: What Lies Ahead?

    On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.

    By Sarah Collins
  • uploads///pill _
    Company & Industry Overviews

    Sanofi Stock: How Much Upside Potential Does Wall Street See?

    In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Elanco, Eli Lilly’s Animal Health Business

    Eli Lilly’s Elanco reported a 1% YoY (year-over-year) rise in revenue to $792.1 million in the second quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Cardiovascular Products Have Been Faring

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Eli Lilly’s Earnings Quality and Dividend Performance

    Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Eli Lilly’s Market Cap and Shareholding Pattern

    Eli Lilly and Company’s (LLY) market cap is ~$106.0 billion as of September 26.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Eli Lilly’s Valuation as of September 27?

    Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///rawpixel  unsplash
    Company & Industry Overviews

    Eli Lilly’s Stock Performance in September

    Eli Lilly stock reported a ~0.6% rise to close at $106.31 on September 26 compared to the previous day’s close.

    By Mike Benson
  • uploads///Chart
    Healthcare

    Comparing Pfizer Stock and Eli Lilly Stock

    Eli Lilly and Company (LLY) stock has fallen a marginal ~0.1% so far in September, and its closing price was $105.59 on September 24.

    By Mike Benson
  • uploads///Chart
    Healthcare

    Comparing Pfizer Stock and Merck and Co. Stock

    Merck & Co. (MRK) stock has risen ~3.2% in the same period, with a closing price of $70.78 on September 24.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Pfizer’s Market Cap and Shareholding Pattern

    The total number of Pfizer’s outstanding shares is ~5.862 billion. Of these, its free-floating shares total ~5.859 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Assessing Pfizer’s Global Performance

    Pfizer reported a rise in revenue in international markets in the second quarter, though this growth was offset by lower sales in US markets.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Revenue and EPS Growth Rate

    Pfizer (PFE) reported EPS of $0.74 on revenue of ~$13.5 billion in the second quarter, surpassing Wall Street analysts’ consensus estimate.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Driving Pfizer’s Revenue?

    Pfizer has divided its product portfolio into two segments: Innovative Health and Essential Health. It reports revenue for both these segments.

    By Mike Benson
  • uploads///rawpixel  unsplash
    Company & Industry Overviews

    Analyzing Perrigo’s Spin-Off of Its Rx Business

    In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.

    By Kenneth Smith
  • uploads///LLY elanco spinoff
    Company & Industry Overviews

    A Look at Eli Lilly’s Elanco Spin-Off

    Eli Lilly (LLY) is expected to post revenues of $24.33 billion in fiscal 2018 and $24.8 billion in fiscal 2019.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s SpotLyte and Lumivive System

    SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

    By Mike Benson
  • uploads///Chart
    Healthcare

    A Closer Look at the Allergan–Bonti Deal

    On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Allergan’s Stock Price Performance in September

    On September 21, 23 analysts tracked Allergan (AGN) stock. Four analysts recommended a “strong buy,” and 12 analysts recommended a “buy.”

    By Mike Benson
  • uploads///Chart  Allergan
    Company & Industry Overviews

    Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates

    Allergan (AGN) reported revenue of $4.1 billion in the second quarter, a 2.9% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///Chart  Merck
    Company & Industry Overviews

    Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates

    Merck & Co. (MRK) reported revenue of ~$10.5 billion in the second quarter, a 5% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///Chart  Pfizer
    Company & Industry Overviews

    Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates

    Pfizer (PFE) reported revenue of ~$13.5 billion in the second quarter, a 4% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///Chart  Valuation Comparison
    Company & Industry Overviews

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

    By Mike Benson
  • uploads///Chart  EPS Growth Rate
    Company & Industry Overviews

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

    By Mike Benson
  • uploads///Chart  Revenue Growth Rate
    Company & Industry Overviews

    Exploring Pharmaceutical Stocks’ Revenue Growth Rates

    In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series.

    By Mike Benson
  • uploads///Chart  Dividends
    Company & Industry Overviews

    A Look at the Dividends Paid by Pharma Stocks in 2018

    In this article, we’ll discuss the details of the dividends paid by the pharmaceutical stocks under review in this series.

    By Mike Benson
  • uploads///Chart  ETFs
    Healthcare

    How Pharmaceutical ETFs Have Performed in 2018

    The SPDR S&P Pharmaceuticals ETF holds ~5.0% of its total investments in Eli Lilly and Company (LLY).

    By Mike Benson
  • uploads///hans reniers  unsplash
    Healthcare

    These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018

    Pharmaceutical stocks that have surpassed the S&P 500 Index’s returns YTD include Eli Lilly, Pfizer, Merck, Allergan, and GlaxoSmithKline.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.